NG004 in Incomplete Spinal Cord Injury Patients
A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Human Monoclonal Antibody NG004 in Acute, Incomplete Cervical Spinal Cord Injury (SCI) Patients
- Acute Spinal Cord Injury (SCI)
- Spinal Cord Diseases
- Spinal Cord Injuries
- Trauma Nervous System
At a glance
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- NovaGo Therapeutics AG
- Enrolment target
- 120
- Started
- 5 August 2026
- Main results due
- July 2029
- Study sites
- 10
- Registry updated
- 24 September 2026
Can you take part?
- Ages 18 years to 75 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Acute incomplete cervical SCI (Neurological level of injury C1 ≤ lesion ≤ C8) with confirmed classification of American Spinal Injury Association (ASIA) impairment scale (AIS) B, C and D at Screening * 4-28 days post-injury and no earlier than 4 days after spinal surgery * No required mechanical ventilation or patients that do not completely depend on mechanical ventilation * Hemodynamically and clinical stable patient according to the acute SCI condition at baseline Exclusion Criteria: * Trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds * Multiple levels of clinically relevant spinal cord lesions * Major brachial or lumbar plexus damage/trauma * Significant head trauma or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function * Other significant pre-existing or current severe systemic disease * History of or an episode of multiple sclerosis or Guillain-Barre syndrome * History of recent meningitis or meningoencephalitis * History of refractory epilepsy * Patients with uncontrolled bleeding diathesis and/or who require concomitant therapeutic anticoagulation and not related to SCI * Presence of any unstable medical or psychiatric condition * Drug dependence any time within the last 6 months before Screening * Pregnant or nursing women * History of a life-threatening allergic or immune-mediated reaction * Presence of infection around the location where the spinal needle insertions are planned for applying the intrathecal injections * Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations * Patients who are unconscious
What this study is about
In the sponsor’s own words, from the registry.
This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI. The trial will evaluate the safety and tolerability, PK, and effects on motor function and daily life functioning of NG004 compared with placebo.
Study sites(10)
Klinik für Querschnittgelähmte, Klinikum Bayreuth
Bayreuth, Germany
Recruiting
BG Universitätsklinikum Bergmannsheil
Bochum, Germany
Not yet recruiting
Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost
Halle, Germany
Not yet recruiting
BG Klinikum Hamburg
Hamburg, Germany
Not yet recruiting
Klinik für Paraplegiologie, Universitätsklinikum Heidelberg
Heidelberg, Germany
Not yet recruiting
Zentrum für Rückenmarksverletzte, Unfallklinik Murnau
Murnau am Staffelsee, Germany
Not yet recruiting
BG Klinik Tübingen
Tübingen, Germany
Recruiting
REHAB Basel
Basel, Switzerland
Recruiting
Swiss Paraplegic Centre
Nottwil, Switzerland
Recruiting
Universitätsklinik Balgrist
Zurich, Switzerland
Recruiting
Showing 10 of 10 sites. 5 of the 10 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07840196. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me